AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1800180 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 5
Study 6354644 — intervention group
Group type: EXPERIMENTAL
Intervention: One rubber band ligation
Number of subjects: 100
Study 6354644 — intervention group
Group type: EXPERIMENTAL
Intervention: Two rubber band ligations
Number of subjects: 100
Study 6354644 — intervention group
Group type: EXPERIMENTAL
Intervention: Three rubber band ligations
Number of subjects: 100
Study 6354644 — intervention group
Group type: COMPARATOR
Intervention: Multiple rubber band ligations (two or three)
Number of subjects: 100
Study 30813805 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D-printed cast
Number of subjects: 16
Study 30813805 — intervention group
Group type: COMPARATOR
Intervention: Fiberglass cast
Number of subjects: 16
Study 31415608 — intervention group
Group type: EXPERIMENTAL
Intervention: On-demand medication
Number of subjects: 0
Study 28597542 — intervention group
Group type: EXPERIMENTAL
Intervention: GDPT (gemcitabine, cisplatin, prednisone, thalidomide)
Number of subjects: 103
Study 28597542 — intervention group
Group type: COMPARATOR
Intervention: CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone)
Number of subjects: 103
Study 26015316 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein/low-carbohydrate diet (diet HP)
Number of subjects: 211
Study 26015316 — intervention group
Group type: COMPARATOR
Intervention: Standard hypocaloric diet (diet S)
Number of subjects: 211
Study 24716721 — intervention group
Group type: EXPERIMENTAL
Intervention: Viewing pictures of a romantic partner
Number of subjects: 0
Study 24716721 — intervention group
Group type: COMPARATOR
Intervention: Viewing pictures of an equally attractive and familiar acquaintance
Number of subjects: 0
Study 21814190 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampicin (RIF) with efavirenz (EFV)
Number of subjects: 182
Study 21814190 — intervention group
Group type: COMPARATOR
Intervention: Efavirenz (EFV) without rifampicin (RIF)
Number of subjects: 182
Study 18584227 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramelteon 8 mg
Number of subjects: 25
Study 18584227 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 17552954 — intervention group
Group type: EXPERIMENTAL
Intervention: Androgen deprivation (AD) for 12 months
Number of subjects: 43
Study 15029330 — intervention group
Group type: EXPERIMENTAL
Intervention: Participatory education intervention
Number of subjects: 0
Study 15029330 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 11803715 — intervention group
Group type: EXPERIMENTAL
Intervention: Variolink High Viscosity
Number of subjects: 26
Study 11803715 — intervention group
Group type: EXPERIMENTAL
Intervention: Enforce
Number of subjects: 26
Study 11803715 — intervention group
Group type: EXPERIMENTAL
Intervention: Geristore
Number of subjects: 26
Study 9509564 — intervention group
Group type: COMPARATOR
Intervention: SIRS patients without acute renal failure (non-ARF)
Number of subjects: 35
Study 9509564 — intervention group
Group type: EXPERIMENTAL
Intervention: SIRS patients with acute renal failure (ARF)
Number of subjects: 35
Study 9509564 — intervention group
Group type: EXPERIMENTAL
Intervention: SIRS patients with ARF
Number of subjects: 35
Study 9509564 — intervention group
Group type: EXPERIMENTAL
Intervention: SIRS patients (both ARF and non-ARF)
Number of subjects: 35
Study 9509564 — intervention group
Group type: EXPERIMENTAL
Intervention: SIRS patients with both ARF and ARDS
Number of subjects: 35
Study 8092504 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 micrograms clonidine
Number of subjects: 30
Study 8092504 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 micrograms clonidine
Number of subjects: 30
Study 8092504 — intervention group
Group type: EXPERIMENTAL
Intervention: 450 micrograms clonidine
Number of subjects: 30
Study 3170992 — intervention group
Group type: EXPERIMENTAL
Intervention: Allergoid treatment
Number of subjects: 25
Study 3170992 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 25
Study 31112513 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard report with additional epidemiological information
Number of subjects: 247
Study 31112513 — intervention group
Group type: COMPARATOR
Intervention: Standard imaging report
Number of subjects: 247
Study 27088370 — intervention group
Group type: EXPERIMENTAL
Intervention: External focus of attention (EFA)
Number of subjects: 15
Study 27088370 — intervention group
Group type: COMPARATOR
Intervention: Internal focus of attention (IFA)
Number of subjects: 15
Study 27088370 — intervention group
Group type: COMPARATOR
Intervention: Control instructions
Number of subjects: 15
Study 27088370 — intervention group
Group type: COMPARATOR
Intervention: Expert athletes
Number of subjects: 15
Study 26330567 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel plus aspirin
Number of subjects: 1089
Study 26330567 — intervention group
Group type: COMPARATOR
Intervention: Aspirin alone
Number of subjects: 1089
Study 23544105 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepolizumab
Number of subjects: 1131
Study 23544105 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1131
Study 22340224 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil 0.2 µg/kg
Number of subjects: 105
Study 22340224 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 2 µg/kg
Number of subjects: 105
Study 22340224 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 105
Study 19057893 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiamine therapy (3 x 100 mg capsules per day for 3 months)
Number of subjects: 40
Study 19057893 — intervention group
Group type: COMPARATOR
Intervention: Placebo (3 capsules per day for 3 months)
Number of subjects: 40
Study 19057893 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiamine therapy
Number of subjects: 40
Study 19057893 — intervention group
Group type: COMPARATOR
Intervention: Thiamine therapy and Placebo
Number of subjects: 40
Study 17464511 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily loratadine 10 mg-pseudoephedrine 240 mg sustained release tablets
Number of subjects: 48
Study 17464511 — intervention group
Group type: COMPARATOR
Intervention: Twice-daily loratadine 5 mg-pseudoephedrine 120 mg combination tablets
Number of subjects: 48
Study 14675743 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolactin response to meta-chlorphenylpiperazine (m-CPP) challenge in borderline subjects with high HAM-A and HAM-D scores
Number of subjects: 52
Study 14675743 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolactin response to meta-chlorphenylpiperazine (m-CPP) challenge in borderline subjects with high BIS scores
Number of subjects: 52
Study 14675743 — intervention group
Group type: COMPARATOR
Intervention: Cortisol response to m-CPP challenge
Number of subjects: 52
Study 14675743 — intervention group
Group type: COMPARATOR
Intervention: Cholinergic and noradrenergic challenges
Number of subjects: 52
Study 11843736 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 degrees left table tilt position (n = 31)
Number of subjects: 60
Study 11843736 — intervention group
Group type: COMPARATOR
Intervention: Full left lateral position (n = 29)
Number of subjects: 60
Study 9924909 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone interview (T)
Number of subjects: 139
Study 9924909 — intervention group
Group type: COMPARATOR
Intervention: Self-administration (S)
Number of subjects: 139
Study 7774736 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostin E2 and amniotomy later (Group A)
Number of subjects: 90
Study 7774736 — intervention group
Group type: EXPERIMENTAL
Intervention: Low amniotomy and oxytocin titration (Group B)
Number of subjects: 90
Study 7774736 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-cervical Foley balloon overnight followed by low amniotomy and oxytocin titration (Group C)
Number of subjects: 90
Study 2183884 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (20 mg twice daily for 1 week)
Number of subjects: 14
Study 2183884 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (20 mg twice daily for 2 weeks)
Number of subjects: 14
Study 452602 — intervention group
Group type: EXPERIMENTAL
Intervention: L-dopa plus decarboxylase inhibitors (carbidopa, benserazide)
Number of subjects: 20
Study 452602 — intervention group
Group type: EXPERIMENTAL
Intervention: Madopar
Number of subjects: 20
Study 452602 — intervention group
Group type: EXPERIMENTAL
Intervention: Sinemet
Number of subjects: 20
Study 452602 — intervention group
Group type: EXPERIMENTAL
Intervention: Switching between Sinemet and Madopar
Number of subjects: 20
Study 452602 — intervention group
Group type: EXPERIMENTAL
Intervention: L-dopa (plasma levels)
Number of subjects: 20
Study 31470828 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 840
Study 28056897 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated care model including screening for cardiovascular risk factors, lifestyle interventions, linkage to primary health care, and active follow-up of intervention adherence.
Number of subjects: 1480
Study 28056897 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated care model (intervention group)
Number of subjects: 1480
Study 28056897 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified in the abstract.
Number of subjects: 1480
Study 26498238 — intervention group
Group type: COMPARATOR
Intervention: Placebo acupuncture (three times per week for three consecutive weeks)
Number of subjects: 86
Study 23474270 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intake of folate
Number of subjects: 234
Study 23474270 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intake of vitamin C
Number of subjects: 234
Study 23474270 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intake of calcium
Number of subjects: 234
Study 23474270 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intake of protein
Number of subjects: 234
Study 23474270 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intake of carbohydrates
Number of subjects: 234
Study 23474270 — intervention group
Group type: EXPERIMENTAL
Intervention: Meeting US dietary guidelines for fruit
Number of subjects: 234
Study 23474270 — intervention group
Group type: EXPERIMENTAL
Intervention: Meeting US dietary guidelines for vegetables
Number of subjects: 234
Study 23474270 — intervention group
Group type: EXPERIMENTAL
Intervention: Average daily energy intake
Number of subjects: 234
Study 21441783 — intervention group
Group type: EXPERIMENTAL
Intervention: RV5 between doses 1 and 2
Number of subjects: 0
Study 21441783 — intervention group
Group type: EXPERIMENTAL
Intervention: RV5 between doses 2 and 3
Number of subjects: 0
Study 21441783 — intervention group
Group type: EXPERIMENTAL
Intervention: RV5 in Analysis B
Number of subjects: 0
Study 19743457 — intervention group
Group type: EXPERIMENTAL
Intervention: CoQ10 at 2,700 mg/day for 9 months
Number of subjects: 185
Study 19743457 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 185
Study 17570973 — intervention group
Group type: EXPERIMENTAL
Intervention: artemether-lumefantrine (n = 47)
Number of subjects: 98
Study 17570973 — intervention group
Group type: COMPARATOR
Intervention: chloroquine (n = 51)
Number of subjects: 98
Study 15117088 — intervention group
Group type: EXPERIMENTAL
Intervention: Vardenafil 10 mg
Number of subjects: 566
Study 15117088 — intervention group
Group type: EXPERIMENTAL
Intervention: Vardenafil 20 mg
Number of subjects: 566
Study 15117088 — intervention group
Group type: EXPERIMENTAL
Intervention: Vardenafil 10 mg and 20 mg
Number of subjects: 566
Study 11692016 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (n=49)
Number of subjects: 135
Study 11692016 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose low-molecular-weight heparin (LMWH) (n=86)
Number of subjects: 135
Study 11692016 — intervention group
Group type: COMPARATOR
Intervention: Both Aspirin and LMWH
Number of subjects: 135
Study 9515282 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril (2.5 mg bid)
Number of subjects: 78
Study 9515282 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone (25 mg tid)
Number of subjects: 78
Study 9515282 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study 9515282 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril
Number of subjects: 78
Study 9515282 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 78
Study 8410124 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous BMT (95 patients)
Number of subjects: 572
Study 8410124 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (96 patients)
Number of subjects: 572
Study 8410124 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic BMT (group 1, 116 patients)
Number of subjects: 572
Study 3511861 — intervention group
Group type: EXPERIMENTAL
Intervention: Azathioprine
Number of subjects: 31
Study 3511861 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 31669503 — intervention group
Group type: EXPERIMENTAL
Intervention: Beetroot juice (BRJ)
Number of subjects: 22
Study 31669503 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 30614171 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (24 international units)
Number of subjects: 34
Study 30614171 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 28419992 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended slow-dose transfusion (ESDT), half an SDP unit administered over 4 hours
Number of subjects: 49
Study 28419992 — intervention group
Group type: COMPARATOR
Intervention: Standard single-donor platelet (SDP) transfusions
Number of subjects: 49
Study 25910523 — intervention group
Group type: EXPERIMENTAL
Intervention: Endeavor zotarolimus‐eluting stents
Number of subjects: 8719
Study 25910523 — intervention group
Group type: EXPERIMENTAL
Intervention: Cypher sirolimus‐eluting stents
Number of subjects: 8719
Study 25910523 — intervention group
Group type: EXPERIMENTAL
Intervention: Early ST (≤30 days)
Number of subjects: 8719
Study 25910523 — intervention group
Group type: EXPERIMENTAL
Intervention: Late ST (>30 and ≤360 days)
Number of subjects: 8719
Study 25910523 — intervention group
Group type: EXPERIMENTAL
Intervention: Very late ST (>360 days)
Number of subjects: 8719
Study 25910523 — intervention group
Group type: COMPARATOR
Intervention: Patients without ST
Number of subjects: 8719
Study 25910523 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined rates of cardiac death and myocardial infarction
Number of subjects: 8719
Study 24220487 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg metoclopramide (group A)
Number of subjects: 150
Study 24220487 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg gabapentin (group B)
Number of subjects: 150
Study 24220487 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg chlorpromazine (group C)
Number of subjects: 150
Study 24220487 — intervention group
Group type: COMPARATOR
Intervention: Placebo (group E)
Number of subjects: 150
Study 24220487 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg dexamethasone (group D)
Number of subjects: 150
Study 21435612 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stent (SES)
Number of subjects: 150
Study 21435612 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stent (EES)
Number of subjects: 150
Study 18562435 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg of alprazolam
Number of subjects: 20
Study 18562435 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 17374064 — intervention group
Group type: EXPERIMENTAL
Intervention: Open chamber device
Number of subjects: 10
Study 17374064 — intervention group
Group type: COMPARATOR
Intervention: Closed chamber device
Number of subjects: 10
Study 17374064 — intervention group
Group type: EXPERIMENTAL
Intervention: Both devices
Number of subjects: 10
Study 15049988 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical resiniferatoxin (maximum dose of 1 micro mol/L)
Number of subjects: 20
Study 11386405 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric muscle strength measurements for 16 muscle actions around the knees and hips.
Number of subjects: 122
Study 11386405 — intervention group
Group type: EXPERIMENTAL
Intervention: Indices of muscle strength derived from measurements (five alternative approaches).
Number of subjects: 122
Study 11386405 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of muscle strength around affected joints vs. unaffected joints.
Number of subjects: 122
Study 9149606 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PTX) 1,200 mg/d for 4 days prior to exposure and 400 mg on exposure day
Number of subjects: 10
Study 9149606 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL) for 4 days prior to exposure and 400 mg on exposure day
Number of subjects: 10
Study 9149606 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PTX)
Number of subjects: 10
Study 9149606 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 10
Study 8498093 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenobarbital
Number of subjects: 4
Study 8498093 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampin
Number of subjects: 4
Study 8498093 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette smokers
Number of subjects: 4
Study 8498093 — intervention group
Group type: COMPARATOR
Intervention: Untreated controls
Number of subjects: 4
Study 3559492 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge of Family APGAR score (known group)
Number of subjects: 0
Study 3559492 — intervention group
Group type: COMPARATOR
Intervention: Unknown Family APGAR score (unknown group)
Number of subjects: 0
Study 3559492 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with self-reported family dysfunction (APGAR < 6)
Number of subjects: 0
Study 2506661 — intervention group
Group type: EXPERIMENTAL
Intervention: rt-PA (100 mg on day 1, 50 mg on day 2) plus heparin
Number of subjects: 25
Study 2506661 — intervention group
Group type: EXPERIMENTAL
Intervention: rt-PA (50 mg over 8 hours on days 1 and 2) plus heparin
Number of subjects: 25
Study 2506661 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 25
Study 2506661 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment (rt-PA plus heparin)
Number of subjects: 25
Study 31801872 — intervention group
Group type: EXPERIMENTAL
Intervention: TACE plus sorafenib
Number of subjects: 156
Study 31801872 — intervention group
Group type: COMPARATOR
Intervention: TACE alone
Number of subjects: 156
Study 30555009 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy physical exertion level ≥6 (exertion scale 1-8)
Number of subjects: 762
Study 30555009 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic exertion and isometric resistance
Number of subjects: 762
Study 30555009 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedentary individuals (regular vigorous exertion <1 day weekly)
Number of subjects: 762
Study 30555009 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequent regular vigorous physical exertion (>4 days weekly)
Number of subjects: 762
Study 30555009 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotionally charged exertion
Number of subjects: 762
Study 28931647 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextromethorphan (various doses)
Number of subjects: 35
Study 24237752 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual education and counselling
Number of subjects: 90
Study 24237752 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 90
Study 23436259 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg zaleplon
Number of subjects: 40
Study 23436259 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg zaleplon
Number of subjects: 40
Study 23436259 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg zaleplon
Number of subjects: 40
Study 23436259 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg zaleplon
Number of subjects: 40
Study 23436259 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 23436259 — intervention group
Group type: EXPERIMENTAL
Intervention: Zaleplon (all doses)
Number of subjects: 40
Study 21458802 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracytoplasmic morphologically selected sperm injection
Number of subjects: 0
Study 19151570 — intervention group
Group type: COMPARATOR
Intervention: Epirubicin preparation (FarmorubicinRTU)
Number of subjects: 97
Study 19151570 — intervention group
Group type: EXPERIMENTAL
Intervention: Lyophilized formulation of epirubicin (Farmorubicin)
Number of subjects: 97
Study 16557544 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alpha-2b plus ribavirin
Number of subjects: 119
Study 15059413 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone (40 mg, 20 mg, and 10 mg per day for 4 weeks)
Number of subjects: 75
Study 15059413 — intervention group
Group type: EXPERIMENTAL
Intervention: Tripterygium wilfordii multiglycoside (TW, 30-60 mg per day)
Number of subjects: 75
Study 15059413 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin A (CsA, 5-6 mg per kilogram of body weight per day)
Number of subjects: 75
Study 15059413 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF, 16-18 mg per kilogram of body weight per day)
Number of subjects: 75
Study 15059413 — intervention group
Group type: COMPARATOR
Intervention: Control group (anti-thyroid drugs and levo-thyroxine)
Number of subjects: 75
Study 10989721 — intervention group
Group type: EXPERIMENTAL
Intervention: Pefloxacin (15-20 mg/kg per day bid for 14-28 days) in combination with ceftazidime and amikacin
Number of subjects: 21
Study 9315494 — intervention group
Group type: EXPERIMENTAL
Intervention: Trazodone 150 mg/d
Number of subjects: 69
Study 9315494 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study 8403134 — intervention group
Group type: EXPERIMENTAL
Intervention: 24 gauge Sprotte spinal needle
Number of subjects: 93
Study 8403134 — intervention group
Group type: COMPARATOR
Intervention: 27 gauge Quincke spinal needle
Number of subjects: 93
Study 3512419 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral acyclovir for 42 days
Number of subjects: 60
Study 3512419 — intervention group
Group type: COMPARATOR
Intervention: Oral acyclovir for five days followed by placebo for 37 days
Number of subjects: 60
Study 3512419 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment groups
Number of subjects: 60